Qinglin Pei, PhD
Associate Professor
Department:
Biobehavioral Nursing Science
Business Phone:
(352) 273-6394
Business Email:
qlpei@ufl.edu
About Qinglin Pei
My research interests include clinical trials design & analysis, survival analysis, machine learning and Bayesian methodology.
Teaching Profile
Courses Taught
2019-2023
PHC6022 Design and Conduct of Clinical Trials
2016-2017
PHC6050C Biostatistical Methods I
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-6584-4859
Areas of Interest
- Clinical Trials Design & Analysis
- Longitudinal Data Analysis
- Bayesian modeling
- Machine Learning
- Survival Analysis
Publications
2024
Accelerating pediatric hodgkin lymphoma research: the hodgkin lymphoma data collaboration (NODAL).
Journal of the National Cancer Institute.
[DOI] 10.1093/jnci/djae013.
[PMID] 38273668.
2024
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children.
JAMA network open.
7(1)
[DOI] 10.1001/jamanetworkopen.2023.51062.
[PMID] 38241048.
2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children’s Oncology Group study.
British journal of haematology.
201(6):1192-1199
[DOI] 10.1111/bjh.18734.
[PMID] 36922022.
2023
Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy.
International journal of radiation oncology, biology, physics.
116(5):1025-1030
[DOI] 10.1016/j.ijrobp.2023.02.020.
[PMID] 36868525.
2023
Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children’s Oncology Group AHOD 1331 study.
Journal of patient-reported outcomes.
7(1)
[DOI] 10.1186/s41687-023-00653-0.
[PMID] 37947987.
2023
Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children’s Oncology Group Study AHOD0831.
Pediatric blood & cancer.
70(8)
[DOI] 10.1002/pbc.30452.
[PMID] 37243975.
2022
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma.
The New England journal of medicine.
387(18):1649-1660
[DOI] 10.1056/NEJMoa2206660.
[PMID] 36322844.
2022
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
69(6)
[DOI] 10.1002/pbc.29649.
[PMID] 35338689.
2022
Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331
Blood.
140(Supplement 1):6565-6566
[DOI] 10.1182/blood-2022-167188.
2022
Evaluating Disparities in Proton Radiation Therapy Use in AHOD1331, a Contemporary Children’s Oncology Group Trial for Advanced-Stage Hodgkin Lymphoma.
International journal of particle therapy.
8(3):55-57
[DOI] 10.14338/IJPT-21-00012.1.
[PMID] 35127976.
2022
P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL
HemaSphere.
6:39-40
[DOI] 10.1097/01.hs9.0000890912.56229.80.
2022
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children’s Oncology Group.
International journal of radiation oncology, biology, physics.
112(4):890-900
[DOI] 10.1016/j.ijrobp.2021.10.152.
[PMID] 34767937.
2022
Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children’s Oncology Group (COG) AHOD1331 Study
Blood.
140(Supplement 1):6550-6551
[DOI] 10.1182/blood-2022-167046.
2022
Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children’s oncology group trials.
The Lancet. Haematology.
9(1):e49-e57
[DOI] 10.1016/S2352-3026(21)00349-5.
[PMID] 34971582.
2022
T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
HemaSphere.
6:40-40
[DOI] 10.1097/01.hs9.0000890916.12776.84.
2022
Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
Blood.
140(10):1086-1093
[DOI] 10.1182/blood.2022016098.
[PMID] 35763667.
2021
LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
Leukemia & lymphoma.
62(3):606-613
[DOI] 10.1080/10428194.2020.1839651.
[PMID] 33112183.
2021
Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.
Pediatric blood & cancer.
68(9)
[DOI] 10.1002/pbc.29212.
[PMID] 34245210.
2021
Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children’s Oncology Group.
Blood.
137(11):1449-1456
[DOI] 10.1182/blood.2020007225.
[PMID] 33512412.
2020
An evaluation of machine learning techniques to predict the outcome of children treated for Hodgkin-Lymphoma on the AHOD0031 trial: A report from the Children’s Oncology Group.
Applied artificial intelligence : AAI.
34(14):1100-1114
[DOI] 10.1080/08839514.2020.1815151.
[PMID] 33731974.
2020
Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients.
Melanoma research.
30(1):52-61
[DOI] 10.1097/CMR.0000000000000625.
[PMID] 31135600.
2019
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group.
British journal of haematology.
187(1):39-48
[DOI] 10.1111/bjh.16014.
[PMID] 31180135.
2019
Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
37(32):3009-3017
[DOI] 10.1200/JCO.19.00812.
[PMID] 31539308.
2018
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial.
The Lancet. Oncology.
19(9):1229-1238
[DOI] 10.1016/S1470-2045(18)30426-1.
[PMID] 30122620.
2018
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children’s Oncology Group study.
Pediatric blood & cancer.
65(7)
[DOI] 10.1002/pbc.27034.
[PMID] 29528181.
2018
Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
65(12)
[DOI] 10.1002/pbc.27375.
[PMID] 30277639.
2018
Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children’s Oncology Group AHOD0031.
International journal of radiation oncology, biology, physics.
100(5):1119-1125
[DOI] 10.1016/j.ijrobp.2018.01.002.
[PMID] 29722656.
2018
Pericardial effusion in Hodgkin lymphoma: a report from the Children’s Oncology Group AHOD0031 protocol.
Blood.
132(11):1208-1211
[DOI] 10.1182/blood-2018-02-834465.
[PMID] 30061157.
2018
Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children’s Oncology Group.
Cancer.
124(15):3210-3219
[DOI] 10.1002/cncr.31519.
[PMID] 29738613.
2018
Significance of pleural effusion at diagnosis in pediatric Hodgkin lymphoma: a report from Children’s Oncology Group protocol AHOD0031.
Pediatric radiology.
48(12):1736-1744
[DOI] 10.1007/s00247-018-4197-6.
[PMID] 30014200.
2018
Variant histology, IgD and CD30 expression in low-risk pediatric nodular lymphocyte predominant Hodgkin lymphoma: A report from the Children’s Oncology Group.
Pediatric blood & cancer.
65(1)
[DOI] 10.1002/pbc.26753.
[PMID] 28802087.
2017
Hospitalization and Rehospitalization in Parkinson Disease Patients: Data From the National Parkinson Foundation Centers of Excellence
PLoS One.
12(7)
[DOI] 10.1371/purnal.pone.0180425.
2017
Hospitalization and rehospitalization in Parkinson disease patients: Data from the National Parkinson Foundation Centers of Excellence.
PloS one.
12(7)
[DOI] 10.1371/journal.pone.0180425.
[PMID] 28683150.
2017
Locomotor Training and Strength and Balance Exercises for Walking Recovery After Stroke: Response to Number of Training Sessions.
Physical therapy.
97(11):1066-1074
[DOI] 10.1093/ptj/pzx079.
[PMID] 29077960.
2017
Regional variation in post-stroke multidisciplinary rehabilitation care among veteran residents in community nursing homes.
Journal of multidisciplinary healthcare.
10:75-85
[DOI] 10.2147/JMDH.S123905.
[PMID] 28280351.
2016
Applying Triple-Matrix Masking for Privacy Preserving Data Collection and Sharing in HIV Studies.
Current HIV research.
14(2):121-9
[PMID] 26511340.
2016
Concordance and discordance between measured and perceived balance and the effect on gait speed and falls following stroke.
Clinical rehabilitation.
30(3):294-302
[DOI] 10.1177/0269215515578294.
[PMID] 25810426.
2016
Poststroke Rehabilitation and Restorative Care Utilization: A Comparison Between VA Community Living Centers and VA-contracted Community Nursing Homes.
Medical care.
54(3):235-42
[DOI] 10.1097/MLR.0000000000000494.
[PMID] 26807537.
2016
Sex Differences in the Clinical Progression of Parkinson’s Disease.
Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.
45(5):749-56
[DOI] 10.1016/j.jogn.2016.05.002.
[PMID] 27444842.
2016
The Effects of Stroke Type, Locus, and Extent on Long-Term Outcome of Gait Rehabilitation: The LEAPS Experience.
Neurorehabilitation and neural repair.
30(7):615-25
[DOI] 10.1177/1545968315613851.
[PMID] 26498434.
2015
Development of a Review-of-Systems Screening Tool for Orthopaedic Physical Therapists: Results From the Optimal Screening for Prediction of Referral and Outcome (OSPRO) Cohort.
The Journal of orthopaedic and sports physical therapy.
45(7):512-26
[DOI] 10.2519/jospt.2015.5900.
[PMID] 25996361.
2015
Geriatrics Consults Associated With Improved Mortality and Disposition in Hospitalized Elders
Journal of the American Geriatrics Society.
63(1, SI)
2014
Direct evidence for BBSome-associated intraflagellar transport reveals distinct properties of native mammalian cilia.
Nature communications.
5
[DOI] 10.1038/ncomms6813.
[PMID] 25504142.
2014
Recognition and treatment of depressive symptoms in Parkinson’s disease: the NPF dataset.
Journal of Parkinson's disease.
4(4):639-43
[DOI] 10.3233/JPD-140382.
[PMID] 25035310.
Grants
Mar 2023
ACTIVE
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: UNIV OF SOUTHERN CALIFORNIA
via NATL INST OF HLTH NCI
Jul 2022
– Jan 2024
An Integrative Radiogenomic Framework for Predicting Treatment Failure in Adolescents & Young Adults with Hodgkin Lymphoma
Role: Principal Investigator
Funding: EMORY UNIV
via US ARMY MED RES ACQUISITION
Apr 2019
– Feb 2023
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: PUBLIC HLTH INST
via NATL INST OF HLTH NCI
Mar 2014
– Feb 2019
Children's Oncology Group Statistics and Data Center
Role: Project Manager
Funding: NATL INST OF HLTH NCI
Education
Ph.D. in Statistics (Minor: Genetics)
2013
·
University of Wisconsin
Contact Details
Phones:
- Business:
- (352) 273-6394
Emails:
- Business:
- qlpei@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100197
GAINESVILLE FL 32610 - Business Street:
-
1225 CENTER DR
GAINESVILLE FL 32610